Dividend investors have watched the ETF industry stuff shelves with covered-call funds, leveraged income products, and derivative-overlay strategies promising double-digit yields. Some work. Many trade upside for a payout that looks impressive until the underlying strategy runs into a bad market. The three funds covered here take a simpler route. They own dividend-paying U.S. stocks, collect the cash, and pass it through. That is the whole mechanism.
The list: SPDR Portfolio S&P 500 High Dividend ETF (NYSEARCA:SPYD), WisdomTree U.S. High Dividend Fund (NYSEARCA:DHS), and Franklin U.S. Low Volatility High Dividend ETF (NASDAQ:LVHD). Each one solves the same problem, income from equities, through a different construction rule. None use options, leverage, or return-of-capital gimmicks to pad the distribution.
SPYD: The Cheapest Way to Buy the S&P 500’s Highest Yielders
The top of the book reflects that tilt. Recent holdings include CVS Health at 1.75%, Viatris at 1.73%, APA Corp at 1.65%, and Merck at 1.62%, alongside a rotating cast of regional banks, utilities, and integrated energy names. Sector-wise, that lands SPYD heavy in financials, REITs, utilities, and energy, precisely the pockets a growth-oriented S&P 500 investor is underweight.
The cost story is the second reason SPYD anchors this list. State Street runs it at a net expense ratio of 0.07%, one of the lowest ratios in the U.S. dividend ETF category, as detailed in the SPDR SPYD fact sheet. Distributions come quarterly. The trailing 12-month total of $2.03 against a share price of about $51 works out to roughly a 4% yield, and the forward annualized estimate of $2.17 nudges that higher.
The tradeoff shows up as cyclicality in returns. When banks, energy, and REITs are in favor, SPYD outperforms most dividend funds. When they are not, it lags. Investors who want the maximum yield in this group and can stomach the sector concentration get rewarded. Investors who need the ride to be quiet should keep reading.
DHS: Dividend-Weighted, Monthly Paid, Mega-Cap Anchored
WisdomTree runs DHS using a methodology most large ETF issuers do not. The fund weights holdings by the dollar amount of cash dividends each company pays. A firm that writes bigger checks gets a bigger position, regardless of where its stock trades. The result is a portfolio that behaves like a concentrated bet on the largest dividend payers in the U.S. market.
Top holdings include names such as Merck at 4.22%, Altria at 3.74%, ExxonMobil at 3.54%, and AT&T at 3.04%, mature businesses with long payout histories and enough scale to write meaningful checks. The lineup skews toward healthcare, energy, and consumer staples, and it looks quite different from SPYD’s regional-bank-and-utility mix.
Because dividend weighting rewards the biggest absolute payers, DHS looks less contrarian than SPYD. Investors who want their income tied to household-name blue chips rather than distressed high-yielders will find that appealing. Investors chasing the last basis point of yield will find SPYD more efficient.
LVHD: The Contrarian Pick That Trades Yield for a Smoother Ride
The portfolio holds more than 130 positions and leans heavily on utilities, consumer staples, REITs, and telecom. Recent top names include Verizon at 3.10%, Chevron at 3.01%, American Electric Power at 2.77%, and Altria at 2.68%. Assets under management run around $608 million, smaller than SPYD or DHS but liquid enough for individual investors.
The catch shows up in the headline yield. LVHD’s trailing 12-month distribution of about $1.43 against a price near $46 puts the payout closer to the low-3% range at current levels, below the fund’s historical run rate and below the other two names here. The low-volatility screen is doing exactly what it advertises, filtering out the highest-yielding but riskiest names. Quarterly distributions are also lumpy, with recent payments ranging from $0.08 to $0.32. Investors who want a steadier NAV and are willing to accept a lower headline yield in exchange find LVHD the calmest option of the three.
Matching the Fund to the Investor
Contact [email protected] for any questions or corrections.